Significant increases seen in weight during preshutdown and postshutdown years, but no significant difference noted between the two
THURSDAY, June 16, 2022 (HealthDay News) — Changes in weight or body mass index (BMI) seen after the COVID-19 shutdown were not significantly different from those occurring in the preshutdown period, according to a research letter published online June 16 in JAMA Network Open.
Rena R. Wing, Ph.D., from The Miriam Hospital in Providence, Rhode Island, and colleagues examined mean changes in weight and BMI in 102,889 adults who had at least two BMI measures at ambulatory visits during both the year after the COVID-19 shutdown (March 16, 2020, to Nov. 12, 2021) and the year immediately prior to the shutdown (Jan. 1, 2018, to March 15, 2020).
The researchers found that during the preshutdown and postshutdown years, participants had significant increases in weight (mean change, 0.18 and 0.22 kg, respectively), but the difference between the changes was not significant (difference, 0.04 kg). Significantly less weight gain occurred in the postshutdown interval versus the preshutdown interval in a sensitivity analysis that included only patients with all four measures assessed in person. From the preshutdown to postshutdown periods, the percentage of individuals who remained weight-stable decreased by 2 percent, while the percentage who gained or lost 5 percent increased by about 0.7 percent.
“These findings should help to mitigate public health concerns that COVID-19 shutdown orders led to weight gain in adults,” the authors write.
One author disclosed financial ties to Noom.
App Can Help Reduce Interdialytic Weight Gain in Chronic Hemodialysis
Weight Cycling Linked to Increased Loss of Muscle Volume
Weight Regain Seen After Cessation of GLP-1 Receptor Agonists in Adults With Overweight, Obesity
Weight Regain Faster After Stopping Meds Than After Stopping Behavioral Weight Management Programs
Low Hydroxychloroquine Intake, Blood Levels Linked to ASCVD Risk in Lupus
Blinatumomab Improves Event-Free Survival in Children With High-Risk B-Cell ALL
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors
Anifrolumab Tied to Lower Hospitalization, Infection Risk in Lupus